As previously reported, UBS analyst Jay Sole downgraded Bath & Body Works to Neutral from Buy with a price target of $35, down from $58. The firm has become "increasingly bearish" on softlines stocks and reduced its calendar 2023 EPS estimates across its coverage by 10%, on average. Its 2023 EPS estimates are now 13% below consensus for the average stock in its coverage in the space, the firm noted.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BBWI:
- Bath & Body Works downgraded to Neutral from Buy at UBS
- Early notable gainers among liquid option names on March 28th
- Bath & Body Works price target lowered to $48 from $52 at Piper Sandler
- Early notable gainers among liquid option names on March 22nd
- Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations